Therapeutic potentials of mesenchymal stem cell-derived exosomes for major solid malignancies: A narrative systematic review.

IF 5 4区 生物学 Q1 BIOLOGY
Xiujuan Wang, Zhe Pan, Nian Liu, Xunan Dai, Ying Yang, Chun Zhang, Yongsheng Xu
{"title":"Therapeutic potentials of mesenchymal stem cell-derived exosomes for major solid malignancies: A narrative systematic review.","authors":"Xiujuan Wang, Zhe Pan, Nian Liu, Xunan Dai, Ying Yang, Chun Zhang, Yongsheng Xu","doi":"10.5582/bst.2025.01120","DOIUrl":null,"url":null,"abstract":"<p><p>Treatments for solid tumors, the most common malignant neoplasms, are often confounded by tumor microenvironments that impede the achievement of uniform anti-tumor effects throughout the entire malignant mass, which contributes to recurrence and progression, negatively impacting clinical outcomes. Improved treatment methods for solid malignancies are therefore needed. Mesenchymal stromal cells (MSCs) have been investigated for treatments for various types of solid tumor cancers due to their ability to target tumor cells with similar cell surface protein profiles. MSC-derived exosomes (MSC-Exos) elicit many of the tumor cell responses produced by MSC with no potential for differentiation and reduced risks of adverse effects. We surveyed the literature and clinical trials registries to identify studies investigating MSC-Exo-based anti-cancer therapies for gastric cancer, colorectal cancer, breast cancer, lung cancer, brain cancer, pancreatic cancer, and urological malignancies, and summarize the results of relevant studies herein to provide a comprehensive description of the therapeutic effects and potential clinical applications of MSC-Exos for the treatment of solid tumor malignancies. We include a summary of relevant clinical trials performed to date in an attempt to assess the data available regarding MSC-Exo safety, and propose future efforts regarding the requirements for transitioning forward from phase-1, 2 trials.</p>","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioscience trends","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.5582/bst.2025.01120","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Treatments for solid tumors, the most common malignant neoplasms, are often confounded by tumor microenvironments that impede the achievement of uniform anti-tumor effects throughout the entire malignant mass, which contributes to recurrence and progression, negatively impacting clinical outcomes. Improved treatment methods for solid malignancies are therefore needed. Mesenchymal stromal cells (MSCs) have been investigated for treatments for various types of solid tumor cancers due to their ability to target tumor cells with similar cell surface protein profiles. MSC-derived exosomes (MSC-Exos) elicit many of the tumor cell responses produced by MSC with no potential for differentiation and reduced risks of adverse effects. We surveyed the literature and clinical trials registries to identify studies investigating MSC-Exo-based anti-cancer therapies for gastric cancer, colorectal cancer, breast cancer, lung cancer, brain cancer, pancreatic cancer, and urological malignancies, and summarize the results of relevant studies herein to provide a comprehensive description of the therapeutic effects and potential clinical applications of MSC-Exos for the treatment of solid tumor malignancies. We include a summary of relevant clinical trials performed to date in an attempt to assess the data available regarding MSC-Exo safety, and propose future efforts regarding the requirements for transitioning forward from phase-1, 2 trials.

间充质干细胞来源的外泌体对主要实体恶性肿瘤的治疗潜力:叙述系统综述。
实体瘤是最常见的恶性肿瘤,其治疗常常受到肿瘤微环境的干扰,这些微环境阻碍了整个恶性肿块实现均匀的抗肿瘤作用,从而导致复发和进展,对临床结果产生负面影响。因此,需要改进实体恶性肿瘤的治疗方法。由于间充质基质细胞(MSCs)能够靶向具有相似细胞表面蛋白谱的肿瘤细胞,因此已被研究用于各种类型实体肿瘤的治疗。间充质干细胞衍生的外泌体(MSC- exos)引发了许多由间充质干细胞产生的肿瘤细胞反应,没有分化的潜力,降低了不良反应的风险。我们通过查阅文献和临床试验注册表,找出基于MSC-Exos的胃癌、结直肠癌、乳腺癌、肺癌、脑癌、胰腺癌和泌尿系统恶性肿瘤的抗癌研究,并总结相关研究结果,全面描述MSC-Exos治疗实体瘤恶性肿瘤的疗效和潜在的临床应用。我们总结了迄今为止进行的相关临床试验,试图评估有关MSC-Exo安全性的可用数据,并就从1、2期试验过渡的要求提出了未来的努力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
13.60
自引率
1.80%
发文量
47
审稿时长
>12 weeks
期刊介绍: BioScience Trends (Print ISSN 1881-7815, Online ISSN 1881-7823) is an international peer-reviewed journal. BioScience Trends devotes to publishing the latest and most exciting advances in scientific research. Articles cover fields of life science such as biochemistry, molecular biology, clinical research, public health, medical care system, and social science in order to encourage cooperation and exchange among scientists and clinical researchers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信